Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Publisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells.

Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL.

Nat Commun. 2018 Nov 12;9(1):4720. doi: 10.1038/s41467-018-07168-z.

PMID:
30420638
2.

Mammary precancerous stem and non-stem cells evolve into cancers of distinct subtypes.

Bu W, Liu Z, Jiang W, Nagi C, Huang S, Edwards DP, Jo E, Mo Q, Creighton CJ, Hilsenbeck SG, Leavitt AD, Lewis MT, Wong STC, Li Y.

Cancer Res. 2018 Nov 6. pii: canres.1087.2018. doi: 10.1158/0008-5472.CAN-18-1087. [Epub ahead of print]

PMID:
30401712
3.

Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.

Johnston AN, Bu W, Hein S, Garcia S, Camacho L, Xue L, Qin L, Nagi C, Hilsenbeck SG, Kapali J, Podsypanina K, Nangia J, Li Y.

Breast Cancer Res. 2018 May 19;20(1):42. doi: 10.1186/s13058-018-0969-z.

4.

Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice.

Chiang ACA, Fowler SW, Savjani RR, Hilsenbeck SG, Wallace CE, Cirrito JR, Das P, Jankowsky JL.

J Exp Med. 2018 May 7;215(5):1349-1364. doi: 10.1084/jem.20171484. Epub 2018 Apr 6.

5.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

PMID:
29578538
6.

Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.

Niravath P, Chen B, Chapman JW, Agarwal SK, Welschhans RL, Bongartz T, Kalari KR, Shepherd LE, Bartlett J, Pritchard K, Gelmon K, Hilsenbeck SG, Rimawi MF, Osborne CK, Goss PE, Ingle JN.

Clin Breast Cancer. 2018 Feb;18(1):78-87. doi: 10.1016/j.clbc.2017.10.009. Epub 2017 Oct 16.

PMID:
29128193
7.

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.

Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.

PMID:
29110152
8.

Tenascin-C and Integrin α9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment.

San Martin R, Pathak R, Jain A, Jung SY, Hilsenbeck SG, Piña-Barba MC, Sikora AG, Pienta KJ, Rowley DR.

Cancer Res. 2017 Nov 1;77(21):5977-5988. doi: 10.1158/0008-5472.CAN-17-0064. Epub 2017 Sep 15.

9.

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM.

Breast Cancer Res Treat. 2017 Nov;166(1):277-287. doi: 10.1007/s10549-017-4400-8. Epub 2017 Jul 20.

10.

EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells.

Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL.

Nat Commun. 2017 Jun 12;8:15773. doi: 10.1038/ncomms15773. Erratum in: Nat Commun. 2018 Nov 12;9(1):4720.

11.

A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data.

Mo Q, Shen R, Guo C, Vannucci M, Chan KS, Hilsenbeck SG.

Biostatistics. 2018 Jan 1;19(1):71-86. doi: 10.1093/biostatistics/kxx017.

PMID:
28541380
12.

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.

Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R.

Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.

13.

Carbon nanotube capsules enhance the in vivo efficacy of cisplatin.

Guven A, Villares GJ, Hilsenbeck SG, Lewis A, Landua JD, Dobrolecki LE, Wilson LJ, Lewis MT.

Acta Biomater. 2017 Aug;58:466-478. doi: 10.1016/j.actbio.2017.04.035. Epub 2017 May 2.

PMID:
28465075
14.

Retrospective review of genomic testing in breast cancer: Does it improve outcome?

Gastelum GM, Iqbal C, Hilsenbeck SG, Rimawi MF, Niravath P.

Breast Cancer Res Treat. 2017 May;163(1):191-195. doi: 10.1007/s10549-017-4154-3. Epub 2017 Feb 21.

PMID:
28224382
15.

CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT.

Chaudhury A, Cheema S, Fachini JM, Kongchan N, Lu G, Simon LM, Wang T, Mao S, Rosen DG, Ittmann MM, Hilsenbeck SG, Shaw CA, Neilson JR.

Nat Commun. 2016 Nov 21;7:13362. doi: 10.1038/ncomms13362.

16.

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6600-E6609. Epub 2016 Oct 6.

17.

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR.

Clin Cancer Res. 2016 Sep 1;22(17):4291-301. doi: 10.1158/1078-0432.CCR-16-0592. Epub 2016 Jul 12.

18.

Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.

Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH.

Breast Cancer Res Treat. 2016 Aug;158(3):441-54. doi: 10.1007/s10549-016-3892-y. Epub 2016 Jul 8.

19.

Stereotactic Biopsy of Segmental Breast Calcifications: Is Sampling of Anterior and Posterior Components Necessary?

Raj SD, Sedgwick EL, Severs FJ, Hilsenbeck SG, Wang T, Sepulveda KA.

Acad Radiol. 2016 Jun;23(6):682-6. doi: 10.1016/j.acra.2015.12.025. Epub 2016 Apr 1.

PMID:
27052522
20.

Research Resource: Roles for Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) in Systems Metabolism.

Marcelo KL, Ribar T, Means CR, Tsimelzon A, Stevens RD, Ilkayeva O, Bain JR, Hilsenbeck SG, Newgard CB, Means AR, York B.

Mol Endocrinol. 2016 May;30(5):557-72. doi: 10.1210/me.2016-1021. Epub 2016 Mar 22.

21.

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R.

Mol Cancer Res. 2016 May;14(5):470-81. doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10.

22.

Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.

den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH.

Cancer Res. 2016 Apr 1;76(7):1942-53. doi: 10.1158/0008-5472.CAN-14-0673. Epub 2016 Feb 26.

23.

The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression.

Shepherd JH, Uray IP, Mazumdar A, Tsimelzon A, Savage M, Hilsenbeck SG, Brown PH.

Oncotarget. 2016 Mar 15;7(11):13106-21. doi: 10.18632/oncotarget.7437.

24.

HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes.

Nikolai BC, Lanz RB, York B, Dasgupta S, Mitsiades N, Creighton CJ, Tsimelzon A, Hilsenbeck SG, Lonard DM, Smith CL, O'Malley BW.

Cancer Res. 2016 Mar 15;76(6):1463-75. doi: 10.1158/0008-5472.CAN-15-2383. Epub 2016 Feb 1.

25.

Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.

Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, Kerstein RA, Gutierrez S, Petersen AK, Bavle A, Lin FY, López-Terrada DH, Monzon FA, Hicks MJ, Eldin KW, Quintanilla NM, Adesina AM, Mohila CA, Whitehead W, Jea A, Vasudevan SA, Nuchtern JG, Ramamurthy U, McGuire AL, Hilsenbeck SG, Reid JG, Muzny DM, Wheeler DA, Berg SL, Chintagumpala MM, Eng CM, Gibbs RA, Plon SE.

JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5699. [Epub ahead of print]

26.

Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.

Holdman XB, Welte T, Rajapakshe K, Pond A, Coarfa C, Mo Q, Huang S, Hilsenbeck SG, Edwards DP, Zhang X, Rosen JM.

Breast Cancer Res. 2015 Nov 18;17:141. doi: 10.1186/s13058-015-0649-1.

27.

An essential role for Gα(i2) in Smoothened-stimulated epithelial cell proliferation in the mammary gland.

Villanueva H, Visbal AP, Obeid NF, Ta AQ, Faruki AA, Wu MF, Hilsenbeck SG, Shaw CA, Yu P, Plummer NW, Birnbaumer L, Lewis MT.

Sci Signal. 2015 Sep 15;8(394):ra92. doi: 10.1126/scisignal.aaa7355.

PMID:
26373672
28.

Modernizing Eligibility Criteria for Molecularly Driven Trials.

Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL.

J Clin Oncol. 2015 Sep 1;33(25):2815-20. doi: 10.1200/JCO.2015.62.1854. Epub 2015 Jul 20.

PMID:
26195710
29.

Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation.

Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang H, Liao YH, Li Y, Lewis MT, Edwards D, Zwaka TP, Hilsenbeck SG, Medina D, Perou CM, Creighton CJ, Zhang XH, Chang EC.

Cell Rep. 2015 Jul 21;12(3):511-24. doi: 10.1016/j.celrep.2015.06.044. Epub 2015 Jul 9.

30.

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26.

31.

Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer.

Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, Hilsenbeck SG, Rosen JM.

Cancer Discov. 2015 May;5(5):520-33. doi: 10.1158/2159-8290.CD-14-1101. Epub 2015 Mar 3.

32.

Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2.

Holloway KR, Sinha VC, Toneff MJ, Bu W, Hilsenbeck SG, Li Y.

PLoS One. 2015 Jan 30;10(1):e0117239. doi: 10.1371/journal.pone.0117239. eCollection 2015.

33.

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.

Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV.

Breast Cancer Res. 2015 Jan 9;17:3. doi: 10.1186/s13058-014-0508-5.

34.

GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades N.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18261-6. doi: 10.1073/pnas.1421415111. Epub 2014 Dec 8.

35.

The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor.

Karlin KL, Mondal G, Hartman JK, Tyagi S, Kurley SJ, Bland CS, Hsu TY, Renwick A, Fang JE, Migliaccio I, Callaway C, Nair A, Dominguez-Vidana R, Nguyen DX, Osborne CK, Schiff R, Yu-Lee LY, Jung SY, Edwards DP, Hilsenbeck SG, Rosen JM, Zhang XH, Shaw CA, Couch FJ, Westbrook TF.

Cell Rep. 2014 Nov 20;9(4):1318-32. doi: 10.1016/j.celrep.2014.10.011. Epub 2014 Nov 6.

36.

A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.

Niravath P, Tham YL, Wang T, Rodriguez A, Foreman C, Hilsenbeck SG, Elledge R, Rimawi M.

Oncologist. 2015 Jan;20(1):13. doi: 10.1634/theoncologist.2014-0278. Epub 2014 Nov 6.

37.

Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients.

Scollon S, Bergstrom K, Kerstein RA, Wang T, Hilsenbeck SG, Ramamurthy U, Gibbs RA, Eng CM, Chintagumpala MM, Berg SL, McCullough LB, McGuire AL, Plon SE, Parsons DW.

Genome Med. 2014 Sep 17;6(9):69. doi: 10.1186/s13073-014-0069-3. eCollection 2014.

38.

AACR Cancer Progress Report 2014.

Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ.

Clin Cancer Res. 2014 Oct 1;20(19 Suppl):S1-S112. doi: 10.1158/1078-0432.CCR-14-2123. Epub 2014 Sep 16. No abstract available.

39.

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.

Breast Cancer Res. 2014 Sep 11;16(5):430. doi: 10.1186/s13058-014-0430-x.

40.

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.

Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH.

Clin Cancer Res. 2015 Apr 1;21(7):1688-98. doi: 10.1158/1078-0432.CCR-14-0432. Epub 2014 Sep 10.

41.

Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.

Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS.

Nat Commun. 2014 Aug 7;5:4577. doi: 10.1038/ncomms5577.

42.

STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer.

Wei W, Tweardy DJ, Zhang M, Zhang X, Landua J, Petrovic I, Bu W, Roarty K, Hilsenbeck SG, Rosen JM, Lewis MT.

Stem Cells. 2014 Oct;32(10):2571-82. doi: 10.1002/stem.1752.

43.

An epigenomic approach to therapy for tamoxifen-resistant breast cancer.

Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW.

Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.

44.

Pediatric data sharing in genomic research: attitudes and preferences of parents.

Burstein MD, Robinson JO, Hilsenbeck SG, McGuire AL, Lau CC.

Pediatrics. 2014 Apr;133(4):690-7. doi: 10.1542/peds.2013-1592. Epub 2014 Mar 10.

45.

Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis.

Hatcher RJ, Dong J, Liu S, Bian G, Contreras A, Wang T, Hilsenbeck SG, Li Y, Zhang P.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1008-13. doi: 10.1073/pnas.1318124111. Epub 2014 Jan 6.

46.

Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy.

Haricharan S, Dong J, Hein S, Reddy JP, Du Z, Toneff M, Holloway K, Hilsenbeck SG, Huang S, Atkinson R, Woodward W, Jindal S, Borges VF, Gutierrez C, Zhang H, Schedin PJ, Osborne CK, Tweardy DJ, Li Y.

Elife. 2013 Dec 31;2:e00996. doi: 10.7554/eLife.00996.

47.

Participants' recall and understanding of genomic research and large-scale data sharing.

Robinson JO, Slashinski MJ, Wang T, Hilsenbeck SG, McGuire AL.

J Empir Res Hum Res Ethics. 2013 Oct;8(4):42-52. doi: 10.1525/jer.2013.8.4.42.

48.

Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells.

Fan Y, Ge N, Wang X, Sun W, Mao R, Bu W, Creighton CJ, Zheng P, Vasudevan S, An L, Yang J, Zhao YJ, Zhang H, Li XN, Rao PH, Leung E, Lu YJ, Gray JW, Schiff R, Hilsenbeck SG, Osborne CK, Yang J, Zhang H.

J Pathol. 2014 Jan;232(1):75-86. doi: 10.1002/path.4283.

49.

Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer.

Covington KR, Brusco L, Barone I, Tsimelzon A, Selever J, Corona-Rodriguez A, Brown P, Kumar R, Hilsenbeck SG, Fuqua SA.

Breast Cancer Res Treat. 2013 Oct;141(3):375-384. Epub 2013 Sep 28.

50.

Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.

Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC.

Breast Cancer Res. 2013;15(5):R77.

Supplemental Content

Loading ...
Support Center